Page 21 - Christiana Care Focus March 2109

| Pharmacy Services
Formulary Update | February 2019
Medication – Generic/Brand Name
Albuterol solution for nebulization
Carfilzomib/Kyprolis injection
Oxycodone sustained-release tablet
Medication – Generic/Brand Name
Quinidine gluconate injection
Antibiotic Order Indication Requirement
EriBULin/Halaven prescribing restriction
Sodium chloride 23.4 percent injection prescribing restriction
Strength/Size
1.25 mg/3 mL
10 mg & 30 mg vials
15 mg
Comment
Use/Indication
Treatment of bronchospasm
Treatment of multiple myeloma & Waldenstrom macroglobulinemia
Treatment of pain
Comment
Line-item extension
Line-item extension
Line-item extension
Dosage form is no longer manufactured.
The number of antibiotics for which an indication is required at the time of prescribing has been expanded. Antibiotics for which the indication is required are cefazolin, cefepime, cefpodoxime, ceftriaxone, cephalexin, ciprofloxacin, clindamycin, imipenem/cilastatin, levofloxacin, meropenem, metronidazole and piperacillin/ tazobactam.
Prescribing restriction updated to include all FDA-approved indications: (1) treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease that should have included an anthracycline and a taxane, and (2) treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Surgical and neurocritical care intensivists are permitted to order 23.4 percent sodium chloride for refractory elevated intracranial pressure.
CHRISTIANA CARE COMPLIANCE HOTLINE
Christiana Care’s Compliance Hotline can be used to report a violation of any regulation, law or legal requirement as it relates to billing or documentation, 24 hours a day, 7 days a week. Callers may remain anonymous. The toll-free number is: 877-REPORT-0 (877-737-6780).
To learn more about Corporate Compliance, review the Corporate Compliance Policy online or contact Christine Babenko, Corporate Compliance Officer, at 302-623-4693.
FOCUS • MARCH 2019 19
ADDITIONS DELETION
MEDICATION POLICY CHANGE